17:00 , Aug 9, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy A biomanufacturing method could enable...
23:05 , Aug 1, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: July 2018

New Therapeutic Targets and Biomarkers: July 2018...
19:05 , Jul 24, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Malaria Mouse studies suggest an RNA-based vaccine encoding...
22:06 , Jun 14, 2018 |  BC Innovations  |  Translation in Brief

There’s more to MIF

In a May...
22:41 , Jun 5, 2018 |  BC Innovations  |  Distillery Therapeutics

Renal

INDICATION: Renal damage Patient sample, cell culture and mouse studies suggest MIF or its receptor CD74 could help treat ischemia/reperfusion-associated acute kidney injury (AKI). In serum samples from 60 cardiac bypass surgery patients who experienced...
18:48 , May 4, 2018 |  BC Week In Review  |  Clinical News

MediciNova reports additional Phase Ib/IIa data for ibudilast in ALS

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) reported additional data from 51 amyotrophic lateral sclerosis (ALS) patients without non-invasive ventilation in a Phase Ib/IIa trial showing that once-daily 60 mg oral ibudilast (Ketas, AV411, MN-166) plus riluzole non-significantly...
18:47 , May 4, 2018 |  BC Week In Review  |  Clinical News

MediciNova reports additional Phase IIb data for ibudilast in MS

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) reported additional data from the Phase IIb SPRINT-MS trial in 255 patients with primary or secondary progressive multiple sclerosis showing that twice-daily oral ibudilast (Ketas, AV411, MN-166) met the secondary endpoint...
01:23 , Mar 31, 2018 |  BioCentury  |  Strategy

Refashioning Takeda

Takeda Pharmaceutical Co. Ltd.’s potential acquisition of Shire plc appears to be timed to take advantage of the chance to acquire products and a global footprint on the cheap. The combination would create a global...
15:16 , Mar 30, 2018 |  BC Week In Review  |  Clinical News

MediciNova's ibudilast misses in Phase II for methamphetamine dependence

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) reported on March 29 that ibudilast (MN-166) missed the primary endpoint of improving methamphetamine abstinence compared with placebo in a Phase II trial to treat methamphetamine dependence. The trial enrolled about...
18:59 , Mar 29, 2018 |  BC Extra  |  Clinical News

MediciNova sinks after meth dependence failure

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) lost $1.74 (15%) to $10.22 on NASDAQ Thursday after reporting that ibudilast (MN-166) missed the primary endpoint of improving methamphetamine abstinence compared with placebo in a Phase II trial to treat...